Workflow
智飞生物:青少年及成人组分百白破疫苗临床试验申请获受理

Core Viewpoint - The announcement by Zhifei Biological (300122) regarding the acceptance of the clinical trial application for its acellular DTP vaccine for adolescents and adults indicates a significant market opportunity as there are currently no approved vaccines for this demographic in China [1] Group 1 - Zhifei Biological's wholly-owned subsidiary, Zhifei Green Bamboo, has developed a vaccine suitable for individuals aged 7 and above to prevent whooping cough, diphtheria, and tetanus [1] - The vaccine has received the acceptance notice from the National Medical Products Administration for drug clinical trial application [1] - The absence of approved acellular DTP vaccines for adolescents and adults in the domestic market highlights the broad market potential for this product [1]